Skip to content

Our research

The research focus of the WA Kids Cancer Centre is on developing safe new treatments for childhood cancers, including brain cancer, sarcoma, leukaemia and neuroblastoma.

The research focus of the The Kids Cancer Centre is on developing safe new treatments for childhood cancers, including brain cancer, sarcoma, leukaemia and neuroblastoma.

The research of the The Kids Cancer Centre is undertaken by laboratory-based scientists, paediatric oncologists, computational biologists, and many higher degree (mainly PhD) and Honours students. Our research is organised into collaborative programs of laboratory-based and translational research.

Our goal is to discover new therapies - therapies that are more effective and less toxic - to fight the most aggressive cancers in babies and children. Our research focuses on:

  • Harnessing the power of the body's own immune system to fight cancer cells via immunotherapy.
  • Determining why apparently similar cancer cells from individual patients respond differently to treatment.
  • Testing existing drugs and new compounds to improve patient outcomes.
  • Understanding the biology of individual cancers to identify weaknesses to target with therapies.
  • Developing new treatments with industry partners to feed our drug development pipeline.

The WA Kids Cancer Centre has a game changing approach for fighting childhood cancer

Our research strategy is to use our world-first childhood cancer laboratory models to investigate potential new cancer immunotherapies and personalised medicines.

Immunotherapy is an exciting cancer treatment that works by engaging the body’s own immune response to fight the cancer. It promises to be an effective and safe cancer therapy that does not cause the collateral damage of conventional treatments. Immunotherapy has fulfilled this promise for adults with extraordinary results in some cancers. Sadly, the development of immunotherapy treatments for children falls far behind.

Personalised medicine involves performing detailed genetic analysis of individual children with cancer and using the information gained to treat them with drugs that are precisely targeted to the individual tumour. All children with cancer treated in Perth undergo such genetic testing, allowing us to use the genetics of individual’s tumours to inform both treatment development in the laboratory and clinical trial opportunities on the ward.

Our goal is to develop such promising and safe treatments to defeat childhood cancers and reduce the need for toxic chemotherapies and radiotherapies.

If you are interested in potential research collaborations, please contact us.

Latest

Videos

Establishing a Clinically Relevant Radiation Therapy Method for Preclinical Medulloblastoma Research

Craniospinal irradiation (CSI) is a cornerstone of pediatric brain cancer therapy, yet detailed, reproducible protocols for accurate CSI delivery in preclinical mouse models remain scarce, hindering translational research and the development of radiosensitizing strategies. We aimed to establish a clinically relevant, easily replicable radiation therapy protocol for medulloblastoma mouse models, providing a robust platform for preclinical evaluation of novel therapeutic combinations.

Invasive pneumococcal disease in children with acute lymphoblastic leukaemia

To determine the incidence, serotype distribution and clinical outcomes of invasive pneumococcal disease in children with acute lymphoblastic leukaemia following widespread use of pneumococcal conjugate vaccines.

Treatment and Survival Outcomes for Indigenous and Non-Indigenous Australians Within the Victorian Lung Cancer Registry: A Retrospective Cross-Sectional Cohort Study

Our goal was to explore and compare risk factors, patterns of management and survival outcomes in Indigenous compared with non-Indigenous Australian patients using the Victorian Lung Cancer Registry.

Imaging Flow Cytometric Identification of Chromosomal Defects in Paediatric Acute Lymphoblastic Leukaemia

Acute lymphoblastic leukaemia is the most common childhood malignancy that remains a leading cause of death in childhood. It may be characterised by multiple known recurrent genetic aberrations that inform prognosis, the most common being hyperdiploidy.

All publications